Recently developed treatments that cure hepatitis C virus (HCV) will create new opportunities for people with other liver diseases to receive transplanted livers.
Only one-third of Americans who need liver transplants receive them, and shortages are expected to rise as the transplant waiting list continues to grow while the supply of organs remains flat. The research suggests that the benefits of new HCV treatments could spill over to many other diseases that cause end-stage liver failure.